In order to clarify whether the marked inhibition of tumor cell growth observed with the combinatorial treatment was due to a more potent effect on the extracellular-signal regulated kinase 1/2 (ERK1/2) pathway downstream EGFR, we analyzed the extracts of treated cells with a commercial anti-pERK antibody. This evidence concerns the gene EGFR and neoplasm.